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ABSTRACT
Objectives: To assess changes in quality of life and
costs of patients undergoing primary total hip
replacement using the Exeter prosthesis compared
with a hypothetical ‘no surgery’ group.
Design: The incremental quality of life, quality-adjusted
life years (QALYs) and cost of Exeter Primary
Outcomes Study patients was compared with
hypothetical ‘no surgery’ group over 5 years. Scores
from annual SF-36 assessments were converted into
utility scores using an established algorithm and the
QALY gains calculated from pre-operative baseline
scores. Costs included implant costs and length of stay.
Setting: Secondary care hospitals.
Participants: Patients receiving a primary Exeter
implant enrolled in ﬁve of seven Exeter Primary
Outcomes Study centres.
Results: Onaverage,patientsgainedaround0.8QALYs
over 5 years. Younger and male patients or those with
lower body mass index and poorer Oxford Hip Scores
were signiﬁcantly associated with increased QALYs.
Treatment costs for a primary episode of care were just
over £5000 (95% CI £4588 to £5812) per patient.
Compared with ‘no surgery’, the cost per QALY was
£7182 (95% CI £6470 to £7678), and this remained
stable when key cost parameters were varied. The most
likely cost per QALY was between £7058 and £7220.
Olderpatients(age75+)costmore,mainlyduetolonger
average hospital stays and had a higher cost per QALY,
although this remained below £10000.
Conclusions: 85% of cases had a cost of <£20000
per QALY (with 70% having a cost per QALY under
£10000) compared with no surgery. Cases would be
considered cost-effective under currently accepted
thresholds (£25000e£30000) compared with ‘no
surgery’. However, depending on age and severity,
younger patients and more severe patients had below
average cost per QALYs. These results help to conﬁrm
the long-term beneﬁts and cost-effectiveness of total
hip replacement in a wide variety of patients using
well-established implant models such as the Exeter.
However, further and ongoing economic appraisal of
this and other models is required for comparative
purposes.
INTRODUCTION
Hip replacement is one of a few cardinal and
successful operations in the NHS and yet it
has mainly gone unchallenged from a cost-
effective perspective since its inception.
However, with the current ﬁnancial environ-
ment in the NHS, it is important to reassess
the costs and beneﬁts and to dispel any
uncertainties surrounding its cost-effective-
ness for the majority of patients.
Long-term studies of hip replacements
have not provided good conclusive economic
proof, which is surprising, given the longevity
of the procedure. However, implant models
come and go and many get modiﬁed, so the
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ARTICLE SUMMARY
Article focus
- The cost-effectiveness of the Exeter THR
compared with no treatment.
- The quality of life gain and incremental number
of QALYs gained and cost.
- The cost per QALY by age, sex, OHS and BMI.
Key messages
- There have been few good prospective economic
evaluations of THR that measure quality of life,
preoperative severity of disease and control for
prosthesis type.
- THR in EPOS patients was found to be cost-
effective (compared with no treatment). Cost per
QALY was below the accepted NICE threshold in
all groups and under all sensitivity assumptions.
Strengths and limitations of this study
- Longer term follow-up of patients is advanta-
geous in assessing the economic beneﬁts of THR
and this study was exceptional for the length of
time in which this was possible.
- The hypothetical control group could provide
only an indirect comparison with other interven-
tions and prostheses but a sound new estimate
of the absolute cost-effectiveness of THR.
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Open Access Researchﬁeld is not static for economic assessment. It is therefore
important to assess those that are stable and have
endured in practice over many years. The orthopaedic
outcome literature is mainly based on studies of the
implant’s survival and few have incorporated a full
economic analysis. Most economic studies nowadays rely
on modelling, given the limitations of the randomised
controlled trial design and well-designed studies
compare alternative models.
1e3 Good economic studies
of total hip replacement (THR) also need an appro-
priate measure of patient outcome (preferably in terms
of changes in health-related utility) as well as a robust
costing.
45This study has addressed these issues but
further work is now ongoing to assess the longer-term
cost-effectiveness.
PATIENTS AND METHODS
The Exeter Primary Outcomes Study (EPOS) is one of
the largest longitudinal studies of a single prosthesis
undertaken in the UK and continues to follow-up
recipients for 10 years post-operatively. In this seven-
centre study, a case series of 1589 patients underwent hip
replacement with the Exeter implant between March
1999 and February 2002. This retrospective economic
study was undertaken at the 5-year follow-up stage in
patients who had the required outcome data available.
These patients were compared with a hypothetical ‘no
surgery’ group in terms of their additional costs and
outcomes (quality of life (QoL)) from baseline.
The cost of an episode of care (including the opera-
tion) was estimated using the average cost of the implant
(in the year the operation was performed) and the actual
number of bed days used per patient at the Department
of Health reference cost per day (for the year in ques-
tion). The SF-36 patient outcome score was collected
annually in the main study. Provided patients did not die
or were not lost to follow-up, the change in their QoL
between pre-operative assessment and 5-year follow-up
was assessed.
Due to a lack of a control group, the quality-adjusted
life year (QALY) gain could only be compared hypo-
thetically with the QoL estimates that might have
prevailed without surgery. For this, we decided to use
a patient’s pre-operative QoL (as measured by the SF-36
score) as the counterfactual scenario. We recognised
that in reality, without surgery, QoL might have
improved or possibly even deteriorated.
The SF-36 is a multipurpose short-form health survey of
36 questions that yields an eight-scale proﬁle of func-
tional health and well-being as well as psychometrically
based physical and mental health summary measures.
6
However, in the EPOS, completion of this was optional
and only 938 patients had sufﬁciently complete scores for
the economic study. We calculated the overall SF-36 score
following the user’s manual guidance. However, the SF-
36 does not directly provide a utility score, so we used the
Brazier algorithm to convert SF-36 questions to respective
utility scores.
7 This utility score captures a patient’s value
for being in different health states on a scale from
0( ¼ death) to 1 (¼ perfect health). Where some patients
did not have an SF-36 completed every year over the
5 years, we used their previous year’s SF-36 score to derive
the utility score for the missing year. This approach
seemed reasonable, as after the ﬁrst post-operative
assessment, most utility scores for the group as a whole
did not change greatly over remaining years.
We calculated QALY gains made each year compared
with the pre-operative baseline using an ‘area under the
curve’ approach (see ﬁgure 1). In reality, other treat-
ments might have improved this baseline score and
reduced the net potential utility gain found in this study.
On the other hand, we might have assumed the condi-
tion worsened. The direction of change could not be
Figure 1 Schematic calculation
of quality-adjusted life years
(QALYs).
Table 1 Characteristics of participants (n¼938)
Characteristics Minimum Maximum
Age, mean (SD) 62.2 (11.5) 21.0 94.0
Body mass index,
mean (SD)
27.2 (4.8) 15.6 53.3
Oxford Hip Score,
mean (SD)
44.2 (8.0) 13.0 60.0
Male, n (%) 363 (38.7)
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EPOS economicsknown with any certainty and therefore we assumed that
no change occurred in QoL from baseline over the 5-
year period. The QALY gain per patient was calculated
up to the 5-year follow-up period or until the last annual
review before death or revision (whichever occurred
ﬁrst). As the EPOS excluded patients who had revisions,
we could only assume a zero QoL gain after revision had
taken place (although this would be likely to be higher).
As resource use data were not collected in the main
EPOS, we retrospectively constructed a proxy cost per
case. This was based on each episode of care and was
a composite of the national variable cost per day (for the
year in which the surgery was performed) adjusted for
the patient’s own length of stay plus the estimated total
cost of the Exeter implant and other components added
as the ﬁxed cost element. An uplifted value of £7500 was
used for the cost of a revision.
3
Finally, the average cost per QALY was calculated for
patients, assuming a zero cost for no surgery. Again this
would have been unlikely but we felt it was a conservative
assumption (as other treatment costs would be incurred
in reality) reducing the cost difference between the two
options.
Statistical methods
Analyses were carried out in Stata V.10.
8 Bootstrapped,
bias-corrected methods were used to calculate 95% CIs
for costs per QALY.
9 Multiple linear regression was used
to model QALY gains, with standard t-test and F-test used
to evaluate the signiﬁcance of b coefﬁcients and model
ﬁt.
SF-36 dimension scores were calculated using recom-
mended procedures. Missing values were replaced by
scale means if valid responses were available for at least
half of the scale items. For the items used in the utility
scores, we used chained equations (ICE) to estimate the
missing values based on the values of all the other vari-
ables in the data set.
10 This was carried out when fewer
than half of the values for the items used in the calcu-
lation of a utility score (from the SF-36) were missing in
any individual questionnaire. However, where more than
half of the values needed were missing, questionnaires
were excluded from the analysis.
RESULTS
The EPOS data set contained complete information on
1589 patients who received the Exeter implant or partial
component. However, only ﬁve of the seven centres
collected QoL data on 1087 patients. Of these, 938
(86%) had sufﬁcient data to be included in the
economic study. During the 5-year follow-up, there were
4598 potentially useable questionnaires from the 1087
patients. One thousand and eight of these had
completed a baseline score and at least one other follow-
up questionnaire completed in sufﬁcient detail for utility
Table 2 Utility score and change from baseline utility by year
N
Utility score Difference from baseline utility
Mean SD 95% CI Mean difference SD difference 95% CI for difference
Baseline 938 0.537 0.113 0.530 to 0.544
Year 1 835 0.720 0.153 0.709 to 0.730 0.181 0.149 0.171 to 0.191
Year 2 728 0.709 0.159 0.698 to 0.721 0.166 0.151 0.155 to 0.177
Year 3 550 0.705 0.160 0.692 to 0.719 0.173 0.154 0.160 to 0.186
Year 4 389 0.712 0.159 0.696 to 0.728 0.170 0.150 0.156 to 0.185
Year 5 720 0.714 0.157 0.703 to 0.726 0.171 0.155 0.160 to 0.182
Figure 2 Utility score by baseline and subsequent year.
Figure 3 Quality-adjusted life years (QALYs) gained in
Exeter Primary Outcomes Study patients up to 5 years.
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EPOS economicsestimation. Use of the multiple imputation method (see
above) was made to adjust 344 of these surveys. Seventy
people with important missing prognostic indicators
were excluded, leaving 938 subjects for the main
economic analysis. There was good SF-36 completion at
the 5-year follow-up date (77%) with 720 patients having
this maximum follow-up score. There were 69 deaths
and only 17 revisions in the study population within the
5-year follow-up period.
Table 1 shows the characteristics of patients included
in the economic study.
Nearly two-thirds of patients were women. The mean
age of all cases was 62 years, but there was a large SD and
upper and lower ranges. The average patient was not
obese before surgery, although there was considerable
variation in body mass index (BMI). The average patient
fell into the third quintile of severity on the Oxford Hip
Score (OHS).
Changes in utility scores from baseline to Year 5 are
shown in table 2 and ﬁgure 2. The change in utility
scores varied little after the initial large gain in the ﬁrst
post-operative year. The largest component of the
increase in overall utility (around 0.18) was seen in the
ﬁrst year after operation. Much smaller changes were
found in subsequent years. Both the overall SF-36 score
and the individual dimensions that comprise it showed
similar changes during this period. The largest changes
on the SF-36 occurred in physical functioning (a 47
point increase), physical role functioning (+50 points)
and pain (+48 points).
The QALYs gained was calculated over this 5-year
period shown in ﬁgure 3. The majority of patients
(90.7%) gained positive QALYs compared with no
surgery. These gains were approximately normal
distributed around a mean value of 0.8 QALYs (95% CI
0.76 to 0.84). However, a small group of patients (9.3%,
n¼87) lost QALYs (in a theoretical sense, they would
have been better without surgery).
In terms of estimating cost per episode, average length
of stay was 10.8 days (SD 7.3) and the median estimated
cost per patient was £5084 (IQR: £4588e£5812). The
distribution of costs is shown in ﬁgure 4.
Table 3 shows the average QALYs gained and
combined with the average cost to derive a cost per
QALY. In order to take account of variation and uncer-
tainty in these estimates, we calculated the associated CI
using bootstrapping simulation methods. The average
cost per QALY for all 938 subjects was £7182 (95% CI
£6740 to £7678).
Figure 4 Cost of primary hip replacement in Exeter Primary
Outcomes Study patients.
Table 3 Length of stay, estimated cost, QALY gain and cost/QALY for all subjects
N
Length of
stay/day Estimated cost/£ QALY gain Cost per QALY
Mean SD Median IQR Mean 95% CI Mean 95% CI*
All 938 10.8 7.3 5084 4588e5812 0.80 0.76 to 0.84 7182 6740 to 7678
*Bootstrapped, bias-corrected CI, based on 10000 bootstrap replications.
QALY, quality-adjusted life year.
Table 4 Length of stay, estimated cost, QALY gain and cost/QALY by age group
N
Length of
stay/day Estimated cost/£ QALY gain Cost/QALY
Mean SD Median IQR Mean 95% CI Mean 95% CI*
23e49 years 82 9.5 3.0 4776 4356e5767 0.95 0.77 to 1.13 5545 4646 to 6861
50e59 years 149 9.4 5.4 4720 4356e5084 0.87 0.76 to 0.98 5902 5140 to 6824
60e64 years 126 10.3 5.1 4981 4391e5767 0.77 0.65 to 0.88 7410 6266 to 8986
65e69 years 190 9.6 2.8 4981 4588e5654 0.88 0.79 to 0.97 5937 5354 to 6631
70e74 years 162 10.5 4.8 5084 4588e5812 0.72 0.63 to 0.81 7944 6940 to 9234
75e90 years 229 13.7 12.1 5654 4812e6904 0.71 0.63 to 0.80 9570 8174 to 11300
*Bootstrapped, bias-corrected CI, based on 10000 bootstrap replications.
QALY, quality-adjusted life year.
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EPOS economicsWe also analysed the QALYs and cost per QALY by age
group as shown in table 4. As might be expected, QALY
gains were signiﬁcantly lower in older patients, with the
largest gains found in younger patients. Conversely, cost
per QALY increased in older age groups because of the
increased length of stay combined with a lower QALY
gain.
With regard to the baseline OHS, we found that pre-
operative severity was a good predictor of cost-effective-
ness. The poorer the initial score on the OHS, the
greater the QALY gain found and similarly the lower the
cost per QALY. There were signiﬁcant differences in
the cost per QALY between quintile 1 (least severe) and
quintiles 3, 4 and 5 (most severe) and also between
quintiles 3 and 5 (see table 5).
The QALY gain was approximately normally distrib-
uted and therefore linear regression could be carried
out to determine patient and treatment characteristics
associated with total QALYs. Age, BMI and OHS were
signiﬁcantly associated with QALYs gained (see table 6).
Given the limitations of the cost data on which the
study was based, a sensitivity analysis was undertaken to
determine robustness of the cost and cost per QALY
results (see table 7).
Using various cost assumptions, mean estimated cost
per case varied from £4950 to £5516. Given a small
variation in cost, the cost per QALY remained relatively
stable in the range of £7058e£7220. This conﬁrmed that
the cost-effectiveness results were robust and insensitive
to some relatively large changes in cost assumptions.
This is also reassuring in terms of potential variability in
costs between treatment centres and/or surgical practice
that occurs in practice.
A cost per QALY threshold analysis is shown in ﬁgure
5. Over 85% of cases had a cost per QALY of £20000 or
less with 70% of these having a cost per QALY under
£10000 thus making it very cost-effective when
compared hypothetically with no surgery. However, 40
cases had a cost per QALY over £50000. These patients
were largely those where the QoL gain was very small
rather than due to their cost being above average.
DISCUSSION
We have shown that from the perspective of the absence
of surgery, the majority of EPOS subjects were treated
cost-effectively. The value to patients in terms of their
health utility and QALY gains has been demonstrated.
Table 5 Length of stay, estimated cost, QALY gain and cost/QALY by Oxford Hip Score (OHS) quintile
OHS (score band) N
Length stay/
day Estimated cost/£ QALY gain Cost/QALY
Mean SD Median IQR Mean 95% CI Mean 95% CI*
Quintile 1 (13e37) 191 10.2 4.1 5084 4588e6075 0.61 0.52 to 0.70 9188 7893 to 10915
Quintile 2 (38e43) 206 11.3 10.2 4981 4588e5767 0.83 0.74 to 0.91 7102 6126 to 8186
Quintile 3 (44e47) 174 10.4 5.7 4981 4391e5812 0.70 0.61 to 0.80 7907 6814 to 9253
Quintile 4 (48e51) 191 11.0 7.0 5233 4720e6160 0.89 0.79 to 0.99 6628 5830 to 7577
Quintile 5 (52e60) 176 11.2 7.5 5084 4720e5812 0.98 0.87 to 1.08 5924 5189 to 6826
*Bootstrapped, bias-corrected CI, based on 10000 bootstrap replications.
QALY, quality-adjusted life year.
Table 6 Linear regression modelling of quality-adjusted
life years (n¼938)
b Coefﬁcient SE (b) p Value
Age (years)
Centred age  0.009 0.002 <0.001
Centred age
2/100  0.027 0.011 0.012
Sex
Female  0.086 0.045 0.053
Body mass index  0.015 0.005 0.001
Oxford Hip Score 0.017 0.003 <0.001
Model F-statistic (5 df) ¼ 12.74, p<0.0001, R
2¼0.064.
Table 7 Sensitivity analysis for main results
Estimated cost/£ Cost/QALY
Median IQR Mean 95% CI*
Modelling cost entirely due to bed days (no ﬁxed cost element) 4950 4240e5940 7220 6723 to 7748
Fixed cost element reduced by 50% 5012 4410e5870 7197 6725 to 7714
Fixed cost element reduced by 25% 5053 4499e5847 7193 6728 to 7687
Fixed cost element as used 5084 4588e5812 7182 6740 to 7678
Fixed cost element increased by 25% 5115 4669e5777 7167 6728 to 7653
Fixed cost element increased by 50% 5146 4758e5742 7160 6732 to 7641
Totally ﬁxed cost (at 5516) 5516 5516e5516 7058 6679 to 7476
*Bootstrapped, bias-corrected 95% CI, based on 10000 bootstrap replications.
QALY, quality-adjusted life year.
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EPOS economicsBased on reasonably conservative assumptions, the
mean QALYs gained was 0.8 QALYs (95% CI 0.76 to
0.84), while the mean cost per hospital stay was just over
£5000 per patient. Although these costs would have been
more accurate if the study had been undertaken
prospectively, comprehensive data allowed us to build
a reasonably accurate cost proﬁle for each patient. Most
of this cost could be attributed to length of stay,
although the study could not directly account for vari-
ability in the price of implant costs. Uncertainty
surrounding the ﬁxed cost data was examined using
sensitivity analysis and its cost was shown to possibly
increase to £5500 per case. Bootstrapping techniques
increased the robustness of these ﬁndings by reducing
bias by multiple replications of the primary study results.
In terms of cost per QALY, we have shown that THR
may be more sensitive to optimal treatment and care in
the most appropriate patient groups than to local vari-
ations in cost. But such results should be treated with
caution. An actual alternative comparator implant rather
than no surgery would have been more realistic, but no
such data existed in this study. However, we deliberately
made highly conservative assumptions both about cost
and any likely net QALY gain. Furthermore, a probabi-
listic sensitivity analysis demonstrated that THR is likely
to be good value for money even when willingness-to-pay
thresholds are set quite low.
This study conﬁrms what is perhaps implicitly assumed
in every day orthopaedic practice that hip replacement
(using a reliable implant) is worth doing for the majority
of patients. The EPOS patients had their pain, function
and ultimately their QoL improved by the Exeter hip,
even those with above average age, disability and BMI.
RECOMMENDATIONS
Further modelling studies are still needed to establish the
longer-term cost-effectiveness of THR.
9 The most cost-
effective implants will be those with the best survival rates
(and hence the fewest revisions), with the best patient
outcomes and the least cost. More studies of a comparative
nature incorporating economic evaluation would imm-
ensely improve the still imperfect knowledge of the cost-
effectiveness of different THR implants in today’s NHS.
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